Clinical Trial

CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This single-arm, open-label, dose-escalation trial aims to evaluate the safety and efficacy of CEA-targeted CAR-T cells and to obtain their pharmacokinetic profile in patients with advanced colorectal cancer and peritoneal metastases after cytoreductive surgery; the recommended dose will then be derived from these data.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07247396
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Chongqing Precision Biotech Co., Ltd
Conditions Peritoneal Metastases From Colorectal Cancer
Enrollment 12 participants
Start Date 2025-11-03
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-25